Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond
The model's full reasoning — Q3 2018 call → NOWe need to determine if management expresses clear conviction that the business is stepping up to a meaningfully higher level over the coming quarters, and if that conviction is grounded in concrete things already in hand or happening. Let's analyze the transcript. Management discusses Q3 results, Q4 outlook, and some forward-looking statements. They mention growth drivers: Imaging, Automotive, Power Discrete. They talk about strong backlog in Automotive, design wins, Silicon Carbide projects, etc. They also mention some softening in China for Microcontrollers. Key phrases: "We are on track to deliver a year of strong growth", "we anticipate net revenues in 2018 to grow about 16%", "we see a solid fourth quarter ahead", "we confirm that we will have a positive free cash flow for the fourth quarter", etc. But the question is about a step-up over the coming quarters, not just this year. Management does not explicitly say that the business will step up to a meaningfully higher level over the coming year. They talk about Q4 growth, but not a longer-term step-up. They mention some drivers but also acknowledge some softening. They do not express a clear conviction about a step-up ahead beyond the current quarter. They talk about 2018 growth, but not about 2019 or beyond in a specific way. They avoid giving Q1 guidance. They say "we will see" for Q1. Thus, the first half of the condition (stated conviction about a step-up ahead) is not clearly present. They are confident about Q4, but not about a longer-term step-up. They also mention some headwinds in Microcontrollers. Therefore, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.